FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
FDA General

Chem-Tech Inspection Violations

FDA warns Pleasantville, IA-based Chem-Tech about CGMP violations in its manufacturing of finished drugs.

Marketing

Capricor BLA for Duchenne-related Cardiomyopathy

FDA accepts for priority review a Capricor Therapeutics BLA for deramiocel, a cell therapy for treating patients diagnosed with Duchenne muscular dyst...

Biologics

Celltrions Prolia and Xgeva Biosimilars Approved

FDA approves a Celltrion BLA for Stoboclo (denosumab-bmwo), a biosimilar to Amgens Prolia, and Osenvelt (denosumab-bmwo), a biosimilar to Amgens Xgeva...

FDA General

Regulated Companies Fear FDA Cuts Impact

Wired reports that several FDA-regulated companies have informed the Securities and Exchange Commission that their business could be adversely affecte...

EIRS/483s

Musks DOGE Cancels Leases on 30 FDA Field Offices

Elon Musks Department of Government Efficiency (DOGE) terminates the leases of 30 FDA field offices and laboratories throughout the U.S.

Medical Devices

FDA Clears Damae Medicals deepLive Skin Imager

FDA clears a Damae Medical 510(k) for its deepLive, an artificial intelligence-based imaging tool that provides real-time, three-dimensional visualiza...

Marketing

OPDP Hits Edenbridge Pharma Over Promos

CDER's Office of Prescription Drug Promotion sends an untitled letter to Edenbridge Pharmaceuticals over Hemady promotional materials used at a medica...

Human Drugs

Corcept Files NDA for Cushings Syndrome Drug

FDA accepts for review a Corcept Therapeutics NDA for relacorilant and its use in treating patients with endogenous hypercortisolism (Cushings syndrom...

FDA General

Rusfertide Phase 3 Data Meet Endpoints

Protagonist Therapeutics and Takeda report positive topline results for the Phase 3 VERIFY study that is evaluating rusfertide for treating polycythem...

Human Drugs

Lexicon Taps Pilavapadin 10mg for Phase 3

Lexicon Pharmaceuticals says it will advance pain drug pilavapadin 10mg into a planned Phase 3 trial based on just-announced Phase 2 PROGRESS study re...